Seres Therapeutics (MCRB) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 hits record high as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Burry doubles down on Nebius short after stock surges 34% on earnings
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Home Depot CEO Ted Decker takes medical leave; two executives step in
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Progress Update
May 16, 2016 7:00 AM EDTSER-109 Phase 2 study enrollment complete; results expected in mid-2016
Academic collaborations further microbiome therapeutic leadership in immuno-oncology, rare genetic diseases and other indications
$120 million upfront payment obtained from Nestlé Health Science
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today reported first quarter 2016 financial results and provided an operational progress update.
The first quarter was marked by strong progress extending our leadership position in the development of microbiome therapeutics, said... More
Seres Therapeutics Announces Appointment of Thomas J. DesRosier as Chief Legal Officer and Executive Vice President
May 16, 2016 7:00 AM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics company, announced today that it has appointed Thomas J. DesRosier as Chief Legal Officer and Executive Vice President. DesRosier will be responsible for global legal operations, as well as corporate compliance and quality assurance. He will also act as Secretary for Seres Leadership Team and its Board of Directors.
Tom is a highly seasoned, proven biopharma leader who will strengthen our leadership team at a crucial stage in our growth and development, said Roger Pomerantz, M.D., President, Chief Executive... More
